What this means is the Sofosbuvir patent can be ignored and Malaysia will be able to import generic Sofosbuvir.
So what about Ledipasvir and Daclatasvir, afterall we need 2 drugs.
No this won't impact that but it turns out DNDi, Pharco and Presidio have a rather tidy pan-genotypic NS5A inhibitor called Ravidasvir, which was co-incidentally trialled in Malaysia. This is essentially the same as Velpatasvir.
So no prizes for joining the dots. Sofosbuvir+Ravidasvir - coming to a town near you (at least if you live in Malaysia).